Skip to main content

Market Overview

Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production

Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production
  • Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral therapeutic for the treatment of COVID-19.
  • A part of these non-exclusive voluntary licensing agreements includes Cipla Ltd, Sun Pharmaceutical Industries LimitedDr. Reddy's Laboratories Ltd (NYSE: RDY), Emcure Pharmaceuticals Limitedand Hetero Labs Limited.
  • The partnership will give the companies license to supply Merck's molnupiravir to India and more than 100 low-and middle-income countries following approvals or emergency authorization by local regulatory agencies.
  • Gilead Sciences Inc (NASDAQ: GILD) also came forward to support India amid surging COVID-19 cases. It would give India at least 450,000 vials of its antiviral drug, remdesivir, and help boost production in India.
  • Molnupiravir is an antiviral therapy Merck is developing with Ridgeback Biotherapeutics to treat non-hospitalized COVID-19 patients.
  • Last month the companies announced interim Phase 2 data, demonstrating a significant reduction in the infectious virus in COVID-19 patients after five days of treatment.
  • Price Action: MRK shares are down 0.09% at $77.53 in premarket trading on the last check Tuesday.

Related Articles (MRK + RDY)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19Biotech Government News Health Care Contracts General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at